Cellyan Biotechnology vs DataMeds AI
HKPD and MEDS side by side, both in wholesale trade-non-durable goods. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HKPD and MEDS compare
Cellyan Biotechnology grew revenue faster over the last twelve months (−33.9% versus −77.5% for DataMeds AI).
Cellyan Biotechnology keeps more of each dollar of sales as profit, with a net margin of −8.5% compared with −565% at DataMeds AI.
Cellyan Biotechnology scores higher on the StockData Score (3 against 1 for DataMeds AI), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HKPD | MEDS |
|---|---|---|
| Size and price | ||
| Market cap | – | $2.0M |
| Share price | $1.52 | $0.640 |
| Change, 1 year | −93.5% | −98.0% |
| Beta (5Y) | – | 0.34 |
| Employees | 2 | 35 |
| StockData Score | ||
| Total score | 3 (better) | 1 |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.3× |
| Growth | ||
| Revenue growth (TTM) | −33.9% (better) | −77.5% |
| Profitability | ||
| Gross margin | 10.3% (better) | −92.1% |
| Operating margin | −17.8% (better) | −548% |
| Net margin | −8.5% (better) | −565% |
| FCF margin | −5.9% | – |
| Return on equity | −15.5% (better) | −1707% |
| Return on invested capital | −22.5% (better) | −153% |
| Financial health | ||
| Debt / equity | 0.09 | – |
| Interest coverage | −17.8× | −6.2× (better) |
| Current ratio | 3.86 (better) | 0.14 |
| Altman Z-score | – | −8.90 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 1.5% | 1.7% |
| Held by insiders | 81.9% | – |
| Short interest, % of float | 0.57% | – |
Go deeper
- HKPD stock overview
- HKPD income statement
- HKPD valuation and score
- MEDS stock overview
- MEDS income statement
- MEDS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.